Parkinson Disease, Secondary (diagnostic imaging) < Parkinson Disease, Secondary (drug therapy) < Parkinson Disease, Secondary (enzymology)

Facettes :

List of bibliographic references indexed by Parkinson Disease, Secondary (drug therapy)

Number of relevant bibliographic references: 31.
[0-20] [0 - 20][0 - 31][20-30][20-40]

Ident.	Authors (with country if any)	Title
000424 (2016)	Marc Morissette [Canada] ; Nicolas Morin [Canada] ; Laurent Grégoire [Canada] ; Alex Rajput [Canada] ; Ali H. Rajput [Canada] ; Thérèse Di Paolo [Canada]	Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
000999 (2014)	Nicolas Morin [Canada] ; Vincent A. Jourdain [Canada] ; Thérèse Di Paolo [Canada]	Modeling dyskinesia in animal models of Parkinson disease.
000C50 (2013)	James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. Brotchie	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
001123 (2012)	Laure Chagniel [Canada] ; Christine Robitaille ; Manon Lebel ; Michel Cyr	Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
001756 (2011)	Deepak Gupta [Canada] ; Abraham Kuruvilla [Inde]	Vascular parkinsonism: what makes it different?
001E00 (2009)	Mallika Somayajulu-Ni U [Canada] ; Jagdeep K. Sandhu [Canada] ; Jerome Cohen [Canada] ; Marianna Sikorska [Canada] ; Ts Sridhar [Canada, Inde] ; Anca Matei [Canada] ; Henryk Borowy-Borowski [Canada] ; Siyaram Pandey [Canada]	Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: Neuroprotection and amelioration of symptoms by water-soluble formulation of Coenzyme Q10
002148 (2008)	Leonardo Cortese [Canada] ; Michael P. Caligiuri ; Richard Williams ; Peter Schieldrop ; Rahul Manchanda ; Ashok Malla ; Raj Harricharan	Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
003109 (2001)	C. Zhang [Canada] ; J P Steiner ; G S Hamilton ; T P Hicks ; M O Poulter	Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment.
003545 (2000)	Frédéric Calon ; Marc Morissette ; Martin Goulet ; Richard Grondin ; Pierre J. Blanchet ; Paul J. Bédard ; Thérèse Di Paolo	125I-CGP 64213 Binding to GABAB Receptors in the Brain of Monkeys: Effect of MPTP and Dopaminomimetic Treatments
003804 (1999)	A. F. Miranda [Canada] ; M. A. Sutton [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] ; R. J. Boegman [Canada]	Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus
003839 (1999)	R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon]	Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys
003862 (1998)	C. Shea ; C. Macknight ; K. Rockwood	Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients.
003A98 (1997)	Marc Morissette [Canada] ; Martin Goulet [Canada] ; Jean-Jacques Soghomonian [Canada] ; Pierre J. Blanchet [Canada] ; Frédéric Calon [Canada] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada]	Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy
003C40 (1997)	R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis]	Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys
003F15 (1995)	H. Shinotoh [Canada] ; B J Snow ; K A Hewitt ; B D Pate ; D. Doudet ; R. Nugent ; D P Perl ; W. Olanow ; D B Calne	MRI and PET studies of manganese-intoxicated monkeys.
003F76 (1995)	Céline Gagnon [Canada] ; Baltazar Gomez-Mancilla [Canada] ; Rudolf Markstein [Suisse] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada]	Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
004041 (1995)	Angela Lang [Canada]	Hemiatrophy, juvenile‐onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult‐onset hemiparkinsonism: The spectrum of hemiparkinsonism‐hemiatrophy syndrome
004227 (1994)	Robert Uitti [Canada] ; Barry J. Snow ; Hitoshi Shinotoh ; Francois J. G. Vingerhoets ; Margo Hayward ; Stanley Hashimoto ; John Richmond [Canada] ; Sanford P. Markey [États-Unis] ; Carol J. Markey [États-Unis] ; Donald B. Calne	Parkinsonism induced by solvent abuse
004453 (1993)	B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard	Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors
004457 (1993)	H. Takahashi [Canada] ; B. J. Snow [Canada] ; T. G. Nygaard ; D. B. Calne [Canada]	Clinical heterogeneity of dopa-responsive dystonia : PET observations
004476 (1992)	B. Gomez-Mancilla [Canada] ; P J Bédard	Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Parkinson Disease, Secondary (drug therapy)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Parkinson Disease, Secondary (drug therapy)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Parkinson Disease, Secondary (drug therapy)
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022